Document is current
Any future updates will be listed below
-
Authors
Toyoshima, Kuniyoshi https://orcid.org/0000-0002-5618-3657
Ichiki, Masahiko
Inoue, Takeshi
Shimura, Akiyoshi
Masuya, Jiro
Fujimura, Yota
Higashi, Shinji
Kusumi, Ichiro
-
Funding
Funding for this research was provided by:
Japanese Ministry of Education, Culture, Sports, Science and Technology (16K10194)
Research and Development Grants for Comprehensive Research for Persons with Disabilities from the Japan Agency for Medical Research and Development (JP18dk0307060)
SENSHIN Medical Research Foundation
JSPS KAKENHI (JP20K16662)
- License Information
-
More Information
Article History
Received: 4 June 2021
Accepted: 14 September 2021
First Online: 2 October 2021
Declarations
:
: This research was approved by the Local Ethics Review Board of the Tokyo Medical University (Ethics Approval Number: SH3502). All study procedures were carried out in accordance with the principles in Declaration of Helsinki. All subjects provided written informed consent after receiving an explanation about this research.
: All authors have given consent for publication.
: M. I. received personal compensation from Otsuka Pharmaceutical, Pfizer, Eli Lilly, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Meiji Seika Pharma, Janssen Pharmaceutical, Takeda Pharmaceutical, MSD, Dainippon Sumitomo Pharma, and Eisai; grants from Otsuka Pharmaceutical, Eli Lilly, Eisai, Shionogi, Takeda Pharmaceutical, MSD, and Pfizer; and is a member of the advisory board of Meiji Seika Pharma.J. M. has received personal compensation from Otsuka Pharmaceutical, Eli Lilly, Astellas, and Meiji Yasuda Mental Health Foundation as well as grants from Pfizer. I. K. has received honoraria from Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Janssen Pharmaceutical, Lundbeck, Meiji Seika Pharma, Mochida Pharmaceutical, MSD, Mylan, Novartis Pharma, Ono Pharmaceutical, Otsuka Pharmaceutical, Pfizer, Shionogi, Shire, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, Tsumura, and Yoshitomiyakuhin and has received research/grant support from Asahi Kasei Pharma, Astellas, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Mochida Pharmaceutical, Novartis Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Pharmaceutical, and Tanabe Mitsubishi Pharma.T. I. is a member of the advisory boards of Pfizer, Novartis Pharma, and Mitsubishi Tanabe Pharma and has received personal fees from Mochida Pharmaceutical, Takeda Pharmaceutical, Eli Lilly, Janssen Pharmaceutical, MSD, Taisho Toyama Pharmaceutical, Yoshitomiyakuhin, and Daiichi Sankyo; grants from Shionogi, Astellas, Tsumura, and Eisai; and grants and personal fees from Otsuka Pharmaceutical, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma, Kyowa Pharmaceutical Industry, Pfizer, Novartis Pharma, and Meiji Seika Pharma.Y. F. has received research and grant support from Novartis Pharma, Otsuka Pharmaceutical, Astellas, Dainippon Sumitomo Pharma, and Shionogi.S. H. received honoraria from Dainippon Sumitomo Pharma and Novartis Pharma.A.S. reports personal fees from Eisai, Dainippon Sumitomo Pharma, MSD, Yoshitomi Yakuhin, and Meiji Seika Pharma, outside the submitted work.K. T. does not have any actual or potential conflicts of interest.
